Global Drugs for Schistosomiasis Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs for Schistosomiasis Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
Drugs for Schistosomiasis report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Schistosomiasis market is projected to reach US$ 106.8 million in 2034, increasing from US$ 82 million in 2022, with the CAGR of 3.8% during the period of 2024 to 2034. Demand from S. haematobium and S. mansoni are the major drivers for the industry.
Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.
East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,
Followed by West Africa(20%).
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Schistosomiasis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
Segment by Type
Praziquantel
Oxamniquine
Other
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Drugs for Schistosomiasis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for Schistosomiasis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for Schistosomiasis industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for Schistosomiasis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for Schistosomiasis introduction, etc. Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Drugs for Schistosomiasis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Drugs for Schistosomiasis report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Schistosomiasis market is projected to reach US$ 106.8 million in 2034, increasing from US$ 82 million in 2022, with the CAGR of 3.8% during the period of 2024 to 2034. Demand from S. haematobium and S. mansoni are the major drivers for the industry.
Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.
East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,
Followed by West Africa(20%).
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Schistosomiasis market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
Segment by Type
Praziquantel
Oxamniquine
Other
Segment by Application
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Drugs for Schistosomiasis market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Drugs for Schistosomiasis, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Drugs for Schistosomiasis industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Drugs for Schistosomiasis in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Drugs for Schistosomiasis introduction, etc. Drugs for Schistosomiasis Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Drugs for Schistosomiasis market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices